Search results for "Prostaglandin-Endoperoxide Synthases"

showing 10 items of 60 documents

Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?

2000

The identification and characterisation of the isoenzyme cyclooxygenase 2 (COX-2) stimulated investigations to develop efficient non-steroidal anti-inflammatory drugs with reduced side effects compared to standard NSAIDs. This review will focus on the structural features needed to achieve COX-2 selectivity. Five structural classes can be identified together with a class bearing little or no resemblance to one another in their molecular structure. The most interesting point is the very distinct structure/activity relationship. On the one hand only minor modifications to a particular compound induce a drastic change in its COX selectivity and on the other hand the structural prerequisites in …

Polarity (physics)StereochemistryComputational biologyBiochemistryPyrrole derivativesStructure-Activity RelationshipProstaglandin-Endoperoxide SynthaseDrug DiscoverymedicineAnimalsHumansCyclooxygenase InhibitorsPharmacologyCyclooxygenase 2 InhibitorsMolecular StructureChemistryAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryMembrane ProteinsRecombinant ProteinsIsoenzymesMechanism of actionCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesBenzene derivativesLipophilicityMolecular Medicinemedicine.symptomPharmacophoreSelectivityCurrent Medicinal Chemistry
researchProduct

Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products.

2010

Cigarette smoke is the main cause of chronic obstructive pulmonary disease (COPD), where it can contribute to the observed airway inflammation. PGE(2) is produced within human airways, and both pro- and anti-inflammatory activities have been reported. We quantitated PGE(2) concentrations in induced sputum supernatants from different groups of subjects and correlated the obtained values to neutrophil infiltration as well as to the expression of cyclooxygenase-2 (COX-2). Cigarette smoke extract (CSE) was used to evaluate the effect of smoking on COX-2 and PGE(2) receptor expression as well as on PGE(2) release in neutrophils and alveolar macrophages (AM) obtained from normal donors. The effec…

Pulmonary and Respiratory MedicineMalePhysiologyMacrophageNeutrophilsPulmonary diseaseTobacco smokeDinoprostonePulmonary Disease Chronic ObstructivePhysiology (medical)SmokemedicineCell AdhesionCigarette smokeCOPDHumansProtein IsoformsReceptors Prostaglandin EPGE(2)Respiratory systemcox-2AgedCOPDbiologybusiness.industryMacrophagesRespiratory diseaseNeutrophilSmokingProstaglandin-Endoperoxide SynthaseSputumProtein IsoformCell BiologyMiddle Agedmedicine.diseaseMacrophages; Prostaglandin-Endoperoxide Synthases; Humans; Aged; Protein Isoforms; Neutrophil Infiltration; Smoke; Smoking; Dinoprostone; Receptors Prostaglandin E; Neutrophils; Middle Aged; Sputum; Female; Male; Pulmonary Disease Chronic Obstructive; Cell Adhesionrespiratory tract diseasesNeutrophil InfiltrationProstaglandin-Endoperoxide SynthasesImmunologybiology.proteinFemaleCyclooxygenasebusinessInfiltration (medical)HumanAmerican journal of physiology. Lung cellular and molecular physiology
researchProduct

A new pyrazolo pyrimidine derivative inhibitor of cyclooxygenase-2 with anti-angiogenic activity

2003

In a previous study, we reported a new pyrazolo pyrimidine derivative, N(4)-benzyl-N(6),N(6)-dimethyl-1-1(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidine-6,4-diamine (DPP), which inhibited potently cyclooxygenase-2 activity in intact cell assays with minor activity against cyclooxygenase-1 (IC(50)=0.9 nM for cyclooxygenase-2 versus IC(50)=59.6 nM for cyclooxygenase-1). In the present work, this behaviour was confirmed in vivo by using the 24-h zymosan-injected mouse air pouch model (ID(50)=1.36 nM/pouch for prostaglandin E(2) level). We also studied the possible beneficial effect of DPP in the angiogenesis-dependent murine air pouch granuloma and rat paw carrageenan-induced hyperalgesia models. DP…

Pyrimidinemedicine.medical_treatmentAngiogenesis InhibitorsPharmacologyCarrageenanDinoprostoneMicechemistry.chemical_compoundIn vivomedicineAnimalsEdemaCyclooxygenase InhibitorsRats WistarProstaglandin E2IC50NitrobenzenesPharmacologySulfonamidesGranulomaCyclooxygenase 2 InhibitorsNeovascularization PathologicbiologyTumor Necrosis Factor-alphaZymosanRatsIsoenzymesPyrimidinesEicosanoidchemistryBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesHyperalgesiabiology.proteinPyrazolesFemaleCyclooxygenasemedicine.symptomInterleukin-1Prostaglandin Emedicine.drugEuropean Journal of Pharmacology
researchProduct

Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2.

2004

OBJECTIVE Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase in endothelium. The aim of this study was to investigate the effect of serum from postmenopausal women treated with raloxifene on prostacyclin production by human umbilical vein endothelial cells and on cyclooxygenases-1 and -2. DESIGN Serum was collected from 21 women receiving 60 mg/day of raloxifene, at baseline and at 3 and 6 months. Human umbilical vein endothelial cells were exposed to serum for 24 hours, and prostacyclin production was evaluated in supernatants. Selective inhibitors of cyclooxygenases-1 and -2 (SC-560 and NS-398) were used to investigate the relative contribution of each enzy…

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyUmbilical VeinsEndotheliumCell SurvivalProstacyclinVasodilationUmbilical veinWestern blotInternal medicinemedicineHumansRaloxifeneCyclooxygenase InhibitorsCells CulturedNitrobenzeneschemistry.chemical_classificationSulfonamidesbiologymedicine.diagnostic_testCyclooxygenase 2 Inhibitorsbusiness.industryObstetrics and GynecologyEndothelial CellsMembrane ProteinsMiddle AgedEpoprostenolImmunohistochemistryIsoenzymesPostmenopausemedicine.anatomical_structureEnzymeEndocrinologychemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesRaloxifene Hydrochloridecardiovascular systembiology.proteinCyclooxygenase 1PyrazolesFemaleCyclooxygenasebusinessmedicine.drugMenopause (New York, N.Y.)
researchProduct

Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation.

2000

Many in vitro studies have used cell cultures to focus on the relationships between cyclo-oxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) isoforms. We have investigated the time-course of regulation and the role of COX-2 and iNOS in a model of experimental inflammation in mice, the air pouch injected with zymosan. This study demonstrates that there is an early acute phase (4 h) mediated mainly by eicosanoids, with high levels of prostaglandin E2 (PGE2) produced by cyclo-oxygenase-1. In addition, in the later phase (from 12 h) there is a participation of nitric oxide (NO) and PGE2 accompanied by co-induction of both iNOS and COX-2. These enzymes were detected in migrating leuk…

Time FactorsBlotting WesternAnti-Inflammatory AgentsFluorescent Antibody TechniqueNitric Oxide Synthase Type IIInflammationPharmacologyDexamethasoneDinoprostoneNitric oxidechemistry.chemical_compoundMiceIn vivomedicineLeukocytesAnimalsCyclooxygenase InhibitorsProstaglandin E2NitritePharmacologyInflammationbiologyCyclooxygenase 2 InhibitorsZymosanZymosanGeneral MedicineExudates and TransudatesNitric oxide synthaseIsoenzymeschemistryBiochemistryCell cultureCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme Inductionbiology.proteinEicosanoidsFemalemedicine.symptomNitric Oxide SynthaseColchicinemedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery.

2002

Nonsteroidal anti-inflammatory drugs (NSAID) inhibit cyclooxygenase activity and cause gastrointestinal damage in part by promoting leukocyte accumulation in the mucosa. Our aim was to evaluate the effects of selective blockade of the isoenzymes cyclooxygenase-1 and cyclooxygenase-2 on leukocyte adhesion in vivo. Leukocyte/endothelial cell interactions were examined in rat mesenteric venules before and after treatment with indomethacin, SC-560 (5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole, cyclooxygenase-1 inhibitor), DFP (5,5-dimethyl-3-(2-propoxy)-4-(4-methanesulfonyl)-2(5H)-furanone, cyclooxygenase-2 inhibitor), or SC-560 plus DFP (20 mg/kg, i.v. each). Indomethacin i…

Time FactorsEndotheliumIndomethacinCell CommunicationPharmacologyRats Sprague-DawleyIn vivomedicineBenzene DerivativesCell AdhesionLeukocytesTumor Cells CulturedAnimalsHumansCyclooxygenase InhibitorsMesenteryFuransPharmacologybiologyCyclooxygenase 2 InhibitorsChemistryAnti-Inflammatory Agents Non-SteroidalMembrane ProteinsBiological activityDrug SynergismRatsEndothelial stem cellIsoenzymesmedicine.anatomical_structureMechanism of actionEnzyme inhibitorCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologybiology.proteinCyclooxygenase 1PyrazolesCyclooxygenaseEndothelium Vascularmedicine.symptomBlood vesselEuropean journal of pharmacology
researchProduct

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

1997

International audience; The discovery of at least 2 cyclo-oxygenase (COX) isoenzymes, referred to as COX-1 and COX-2, has updated our knowledge of nonsteroidal anti-inflammatory drugs (NSAIDs). This has lead investigators to reconsider what can be awaited from this class of drugs. The 2 COX isoenzymes share structural and enzymatic similarities, but are specifically regulated at the molecular level and may be distinguished apart in their functions, although some physiological overlap between them does occur. The major goal in developing selective COX inhibitors is to improve NSAID tolerability. Classic NSAIDs preferentially inhibit COX-1 in vitro, but it appears hazardous to judge their gas…

[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH: Prostaglandin-Endoperoxide SynthasesAnti-Inflammatory AgentsPharmacologyNabumetoneMESH: Cyclooxygenase InhibitorsPharmacotherapymedicineMESH : Anti-Inflammatory Agents Non-SteroidalAnimalsHumansPharmacology (medical)Cyclooxygenase InhibitorsMESH: AnimalsAdverse effectMESH: HumansMESH : Prostaglandin-Endoperoxide Synthasesbusiness.industryMESH : HumansAnti-Inflammatory Agents Non-SteroidalMESH : Cyclooxygenase InhibitorsMESH: Anti-Inflammatory Agents Non-SteroidalClinical trial[SDV.AEN] Life Sciences [q-bio]/Food and NutritionMeloxicamTolerabilityProstaglandin-Endoperoxide SynthasesMESH : AnimalsCyclo-oxygenaseNon-Steroidalbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionNimesulidemedicine.drug
researchProduct

Progestogens stimulate prostacyclin production by human endothelial cells.

2005

BACKGROUND: The effects of progestogens on endothelial physiology are poorly studied. Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase (COX) in endothelium. We examined the effects of two clinically used progestogens, progesterone and medroxyprogesterone acetate (MPA), on prostacyclin production by cultured human umbilical vein endothelial cells (HUVEC) and the possible role of progesterone receptors and both COX enzymes. METHODS: Cells were exposed to 1-100 nmol/l of either progesterone or MPA and prostacyclin production was measured in culture medium. RESULTS: Both progestogens significantly increased prostacyclin release in a time- and dose-dependent man…

medicine.medical_specialtyUmbilical VeinsEndotheliumProstacyclinMedroxyprogesterone AcetateUmbilical veinInternal medicineProgesterone receptormedicineMedroxyprogesterone acetateHumansCyclooxygenase InhibitorsReceptorCells CulturedNitrobenzenesProgesteroneSulfonamidesbiologyCyclooxygenase 2 InhibitorsDose-Response Relationship DrugEstradiolRehabilitationObstetrics and GynecologyEndothelial CellsMembrane ProteinsEpoprostenolEndothelial stem cellMifepristoneEndocrinologymedicine.anatomical_structureReproductive MedicineCyclooxygenase 2Prostaglandin-Endoperoxide Synthasescardiovascular systembiology.proteinCyclooxygenase 1PyrazolesCyclooxygenaseEndothelium VascularProgestinsReceptors Progesteronemedicine.drugHuman reproduction (Oxford, England)
researchProduct

Inhibition of the NF-κB Signaling Pathway Mediates the Anti-inflammatory Effects of Petrosaspongiolide M

2003

Petrosaspongiolide M (PT) is a potent secretory phospholipase A(2) inhibitor and anti-inflammatory agent. This marine metabolite reduced the production of nitrite, prostaglandin E(2), and tumor necrosis factor-alpha in the mouse air pouch injected with zymosan. These effects were also observed in mouse peritoneal macrophages stimulated with zymosan. Inhibition of these inflammatory mediators was related to reductions in inducible nitric oxide synthase, cyclo-oxygenase-2, and tumor necrosis factor-alpha expression. Since nuclear factor-kappaB (NF-kappaB) appears to play a central role in the transcriptional regulation of these proteins by macrophages, we investigated the effects of PT on thi…

medicine.medical_treatmentAnti-Inflammatory AgentsNitric Oxide Synthase Type IIBiochemistryDinoprostoneMicechemistry.chemical_compoundPhospholipase A2NF-KappaB Inhibitor alphaCell MovementmedicineAnimalsRNA MessengerOleanolic AcidPhosphorylationNitritesPharmacologybiologyTumor Necrosis Factor-alphaZymosanNF-kappa BZymosanBiological TransportNF-κBDNACell biologyIsoenzymesNitric oxide synthaseIκBαCytokinechemistryBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesModels AnimalMacrophages Peritonealbiology.proteinCytokinesI-kappa B ProteinsTumor necrosis factor alphaNitric Oxide SynthaseSignal TransductionProstaglandin E
researchProduct

A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase

2002

Abstract In a previous study, we reported a new pyrroloquinazoline derivative, 3-(4′-acetoxy-3′,5′-dimethoxy)benzylidene-1,2-dihydropyrrolo[2,1- b ]quinazoline-9-one (PQ), which inhibited human purified 5-lipoxygenase activity and prostaglandin E 2 release in lipopolysaccharide-stimulated RAW 264.7 cells. In the present work, we show that PQ inhibits cyclo-oxygenase-2 activity in intact cell assays (human monocytes) and purified enzyme preparations (ovine isoenzymes) without affecting cyclo-oxygenase-1 activity. This behaviour was confirmed in vivo by using the zymosan-injected mouse air pouch model, where PQ caused a marked reduction in cell migration and leukotriene B 4 levels at 4 h, as …

medicine.medical_treatmentPharmacologyMonocytesMicechemistry.chemical_compoundIn vivomedicineAnimalsEdemaHumansCyclooxygenase InhibitorsPyrrolesLipoxygenase InhibitorsEnzyme InhibitorsProstaglandin E2Pain MeasurementPharmacologyAnalgesicsArachidonate 5-LipoxygenaseSheepCyclooxygenase 2 InhibitorsDose-Response Relationship DrugbiologyChemistryAnti-Inflammatory Agents Non-SteroidalZymosanMembrane ProteinsBiological activityIsoenzymesBiochemistryMechanism of actionCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorArachidonate 5-lipoxygenaseQuinazolinesQuinolinesbiology.proteinFemalemedicine.symptomProstaglandin Emedicine.drug
researchProduct